The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes

References

• WHO Classification of Tumours of the Breast, 4th edition. Washington: WHO; 2012.
   Google Scholar
• Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008;11:541–547.
   Google Scholar
• Oakley GJ III Tubbs RR, Crowe J, et al. HER-2 amplification in tubular carcinoma of the breast. Am J Clin Pathol. 2006;126:55–58.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–352.
   PubMed Web of Science ®Google Scholar
• Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;21:2750–2767.
   Google Scholar
• Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378:1812–1823.
   PubMed Web of Science ®Google Scholar
• Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;16:141–150.
   Google Scholar
• Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. Jco. 2013;1:2783–2790.
   Google Scholar
• Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014;25:339–345.
   PubMed Web of Science ®Google Scholar
• Sestak I, Cuzick J, Dowsett M, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 2015;33:916–922.
   PubMed Web of Science ®Google Scholar
• Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;4:1067–1076.
   Google Scholar
• Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin with Oncotype DX Recurrence Score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. 2016;108:1–7.
   Google Scholar
• Gnant M, Sestak I, Filipits M, et al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol. 2015;26:1685–1691.
   PubMed Web of Science ®Google Scholar
• Dubsky P, Brase JC, Jakesz R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients. Br J Cancer. 2013;109:2959–2964.
   PubMed Web of Science ®Google Scholar
• Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–729.
   PubMed Web of Science ®Google Scholar
• Laenkholm AV, Jensen MB, Eriksen JO, et al. The PAM50 Risk of Recurrence Score Predicts 10year distant recurrence in a comprehensive Danish cohort of 2558 postmenopausal women allocated to 5yr of endocrine therapy for hormone receptor positive early breast cancer. J Clin Oncol. 2018;57, In press.
   Google Scholar
• Ejlertsen B, Jensen MB, Mouridsen HT, et al. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol. 2014;53:174–185.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Ejlertsen B, Jensen MB, et al. Danish Breast Cancer Cooperative Group. Clep. 2016;8:445–449.
   Google Scholar
• Talman ML, Rasmussen BB, Andersen J, et al. Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncologica. 2008;47:789–794.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.
   PubMed Web of Science ®Google Scholar
• Nielsen T, Wallden B, Schaper C, et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014;14:177.
   PubMed Web of Science ®Google Scholar
• Wallden B, Storhoff J, Nielsen T, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genomics. 2015;8:54.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16:5222–5232.
   PubMed Web of Science ®Google Scholar
• NanoString Technologies S. Prosigna Package Insert. Seattle (WA): NanoString Technologies; 2013.
   Google Scholar
• Martinez SR, Beal SH, Canter RJ, et al. Medullary carcinoma of the breast: a population-based perspective. Med Oncol. 2011;28:738–744.
   PubMed Web of Science ®Google Scholar
• Sestak I. Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy. Breast Care (Basel). 2017;12:146–151.
   PubMed Web of Science ®Google Scholar
• Stenkvist B, Bengtsson E, Eriksson O, et al. Histopathological systems of breast cancer classification: reproducibility and clinical significance. J Clin Pathol. 1983;36:392–398.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–172.
   PubMed Web of Science ®Google Scholar
• Heng YJ, Lester SC, Tse GM, et al. The molecular basis of breast cancer pathological phenotypes. J Pathol. 2017;241:375–391.
   PubMed Web of Science ®Google Scholar
• Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. JCO. 2010;28:3271–3277.
   PubMed Web of Science ®Google Scholar
• Sihto H, Lundin J, Lundin M, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res. 2011;13:R87.
   PubMed Web of Science ®Google Scholar
• Bomeisl PE, Thompson CL, Harris LN, et al. Comparison of Oncotype DX Recurrence Score by histologic types of breast carcinoma. Arch Pathol Lab Med. 2015;139:1546–1549.
   PubMed Web of Science ®Google Scholar
• Turashvili G, Brogi E, Morrow M, et al. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. Breast Cancer Res Treat. 2017;165:65–76.
   PubMed Web of Science ®Google Scholar
• Sheffield BS, Kos Z, Asleh-Aburaya K, et al. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. Breast Cancer Res Treat. 2016;155:483–490.
   PubMed Web of Science ®Google Scholar